Abemaciclib (Verzenio)

Key Messages

• CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
• The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec.
• This review assesses abemaciclib (Verzenio), 50 mg, 100 mg, 150 mg, 200 mg oral tablet.
• Indication: In combination with endocrine therapy for the adjuvant treatment of adult patients with HR-positive, HER2-negative, node-positive early breast cancer at high risk of disease recurrence based on clinicopathologic features and a Ki-67 test score ≥ 20%.